ERBB2 and breast cancer: Olaparib has recently (January 2018) received FDA approval for the treatment of patients with gBRCA1/2m HER2-negative metastatic BC who were previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic settings.49 This makes olaparib the first PARPi approved for the treatment of BC.